In 2019, Biogen emerged as a new star with Spinraza.
According to IQVIA, Biogen posted sales of 10 billion in the first quarter(2019 2Q) immediately after reimbursement of Spinraza, followed by 20 billion in the second quarter(3Q), achieving 30 billion in sales during two quarters.
Amgen, whose sales of six products, including Prolia, grew by at least 50%, also stood out.
Cumulative sales in the first three quarters of the year reached 60 billion won, surged 124.9% from the same period in the previous year. It had already surpassed annual sales(39 billion) in the previous year.
In particular, Prolia’s quarterly sales jumped from 4 billion won to 12 billion won thanks to the expanded reimbursement in the first half of the year. It became a best selling product of company surpassing Kyprolis.
Novo Nordisk which sell anti-obesity drug Saxenda, achieved sales above 100 billion won in the three quarters. Cumulative sales in the three quarters rocketed 59.2% year on year to 113 billion won.
Saxenda, which recorded only 1.7 billion won in sales in the third quarter of the previous year, has become a top selling product, increasing sales to 11.9 billion won in one year.
Cumulative sales in three quarters, which did not reach 2 billion in the previous year, increased by 16 times to 31.7 billion won in last year. Due to this, Novo Nordisk, which posted 105.5 billion won in sales for one year in 2018, achieved sales of 113 billion won for three quarters of last year.
Among domestic companies, Celltrion Pharm is showing the strongest momentum. The annual growth rate is more than 50%, and the company is trying to achieve 200 billion annual sales.
Celltrion recorded 141.3 billon won in cumulative sales growing by 57.2% in the three quarters of 2019 on the back of Godex, which is its top selling product and had risen to 10 billion won in quarterly sales, and steep growth of biosimilars Remsima and Herzuma.
Korea Pharma is also expecting to achieve annual sales of 50 billion, recording cumulative sales of 36.5 billion in the three quarters, growing 51.8% year on year thanks to Salopram and Vastia.
Next, Abbvie which sells the hepatitis C treatment Mavyret is recording more than 10 billion won in average annual sales, with sales growing over 30%. MedicaKorea, SamChunDang Pharm, Arlico Pharm also posted nearly 30% growth.
In addition, OnoPharmaKorea achieved cumulative sales of 50 billion in the three quarters with only one product, Opdivo, and showed growth rates over 20% along with other companies including Yungjin Pharm, Daiichi Sankyo.